The immune system, amyloid-β peptide, and Alzheimer's disease
Weksler, Marc E. ; Gouras, Gunnar LU
; Relkin, Norman R.
and Szabo, Paul
(2005)
In Immunological Reviews
205(1).
p.244-256
- Abstract
In this review, the case is made that amyloid-β peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression. This supposition is supported by the capacity of anti-β-amyloid peptide antibodies to prevent or reverse the disease in mouse models of Alzheimer's disease. Furthermore, preliminary results obtained in a small number of patients with Alzheimer's disease are consistent with the observations made in the mouse model of this disease. We review the relationship between the immune system, amyloid-β peptide, and Alzheimer's disease and the progress made in applying immunotherapy to patients... (More)
In this review, the case is made that amyloid-β peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression. This supposition is supported by the capacity of anti-β-amyloid peptide antibodies to prevent or reverse the disease in mouse models of Alzheimer's disease. Furthermore, preliminary results obtained in a small number of patients with Alzheimer's disease are consistent with the observations made in the mouse model of this disease. We review the relationship between the immune system, amyloid-β peptide, and Alzheimer's disease and the progress made in applying immunotherapy to patients with Alzheimer's disease.
(Less)
- author
- Weksler, Marc E.
; Gouras, Gunnar
LU
; Relkin, Norman R.
and Szabo, Paul
- publishing date
- 2005-06
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Immunological Reviews
- volume
- 205
- issue
- 1
- pages
- 244 - 256
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:15882358
- scopus:20344384992
- ISSN
- 0105-2896
- DOI
- 10.1111/j.0105-2896.2005.00264.x
- language
- English
- LU publication?
- no
- id
- 4d86e8cd-527e-4aaf-9149-02fd8864e90e
- date added to LUP
- 2020-02-20 14:42:49
- date last changed
- 2025-10-14 10:44:07
@article{4d86e8cd-527e-4aaf-9149-02fd8864e90e,
abstract = {{<p>In this review, the case is made that amyloid-β peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression. This supposition is supported by the capacity of anti-β-amyloid peptide antibodies to prevent or reverse the disease in mouse models of Alzheimer's disease. Furthermore, preliminary results obtained in a small number of patients with Alzheimer's disease are consistent with the observations made in the mouse model of this disease. We review the relationship between the immune system, amyloid-β peptide, and Alzheimer's disease and the progress made in applying immunotherapy to patients with Alzheimer's disease.</p>}},
author = {{Weksler, Marc E. and Gouras, Gunnar and Relkin, Norman R. and Szabo, Paul}},
issn = {{0105-2896}},
language = {{eng}},
number = {{1}},
pages = {{244--256}},
publisher = {{Wiley-Blackwell}},
series = {{Immunological Reviews}},
title = {{The immune system, amyloid-β peptide, and Alzheimer's disease}},
url = {{http://dx.doi.org/10.1111/j.0105-2896.2005.00264.x}},
doi = {{10.1111/j.0105-2896.2005.00264.x}},
volume = {{205}},
year = {{2005}},
}